Sarepta Therapeutics, Inc.

Sarepta Therapeutics (SRPT) is a US‑based biotechnology company focused on genetic medicines for rare neuromuscular conditions, principally Duchenne muscular dystrophy (DMD). Its portfolio includes exon‑skipping oligonucleotides with prior regulatory approvals and a developing gene‑therapy pipeline aimed at restoring dystrophin expression. The company’s clinical updates, regulatory interactions and manufacturing progress tend to drive short‑term share‑price moves. With a market capitalisation of about $2.44 billion, Sarepta is a small‑to‑mid‑cap biotech where R&D outcomes heavily influence valuation. Investors should note high development costs, potential for binary clinical outcomes and ongoing debates about clinical efficacy in some programmes. Commercial revenues exist but remain modest relative to R&D expenditure, so partnerships and successful trial readouts are key. This content is educational only and not personal financial advice; biotech stocks can be volatile and may suit only investors with a higher tolerance for risk and a longer time horizon.